Showing results (191-200 of 253) with videos related to

Sort By:
Pageof 26
Cancers|August 16, 2020
High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG)Silvia Salmoiraghi, Roberta Cavagna, Pamela Zanghì, et al.
Blood|August 15, 2002
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)Marco Ladetto, Paolo Corradini, Sonia Vallet, et al.
Blood Advances|December 3, 2021
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristicsMehdi Hamadani, Maud Ngoya, Anna Sureda, et al.
Cancer|October 24, 2018
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working PartyAli Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Cancer Medicine|November 6, 2020
The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trialAlessandra Romano, Chiara Pavoni, Francesco Di Raimondo, et al.
Advances in Therapy|May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect ComparisonNoemi Puig, Joris Diels, Suzy van Sanden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Blood|February 2, 2008
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Federica De Marco, Fabio Benedetti, et al.
Leukemia & Lymphoma|January 11, 2025
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVDChiara Rusconi, Angelica Barone, Andrea Visentin, et al.
Pageof 26